Old drug, new hope? thalidomide trial targets rare leukemia
NCT ID NCT06530576
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests thalidomide, a drug once used for other conditions, in 48 people with symptomatic large granular lymphocytic (LGL) leukemia. Participants start on thalidomide alone; if it doesn't work well enough, methotrexate is added. The goal is to see if thalidomide can control the disease and improve blood counts, offering a potential new treatment for this rare leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- thalidomide (with methotrexate added if needed)
- What this could lead to
- If this works, it could point toward a new first-line treatment for LGL leukemia that is simpler and possibly safer than current options.
- What could go wrong
- This is a small, early-phase trial with only 48 people. Thalidomide has known side effects, and the results may not apply to all patients or lead to a standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.